Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial
- PMID: 32192573
- PMCID: PMC7255545
- DOI: 10.1016/S1470-2045(20)30023-1
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial
Abstract
Background: Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children and young adults with recurrent or refractory non-CNS solid tumours or lymphoma.
Methods: We did a multicentre, open-label, single-arm, dose-confirmation and dose-expansion, phase 1-2 trial in 23 hospitals in the USA. Eligible patients for part A (dose-confirmation phase) of the study were aged 1-18 years with solid tumours with measurable or evaluable disease (by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) regardless of histology. Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and melanoma. Patients in part A and were given nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle in a rolling 6 study design with de-escalation upon dose-limiting toxicities to establish the recommended phase 2 dose. Patients in part B were given the recommended phase 2 dose. The primary outcomes were the tolerability, systemic exposure, maximum tolerated dose, and the antitumour activity of nivolumab at the adult recommended dose in children and young adults. This trial is registered with ClinicalTrials.gov, NCT02304458, with follow-up ongoing and is closed to new participants.
Findings: 85 patients were enrolled between Feb 22, 2015, and Dec 31, 2018, and 75 patients were fully evaluable for toxicity. Median follow-up was 30 days (IQR 27-83). In part A, 13 patients were enrolled and 12 were evaluable for toxicity. There were no dose de-escalations or dose-limiting toxicities and nivolumab 3 mg/kg was confirmed as the paediatric recommended phase 2. 72 patients were enrolled in part B and 63 were evaluable for toxicity. Five (7%) patients in part B had dose-limiting toxicities. The most common overall toxicity was anaemia (35 [47%] of 75 patients; five patients had grade 3 or grade 4) and non-haematological toxicity was fatigue (28 [37%] patients; none had grade 3 or grade 4). Responses were observed in patients with lymphoma (three [30%] of ten with Hodgkin lymphoma and one [10%] of ten with non-Hodgkin lymphoma; all responders had PD-L1 expression). Objective responses were not observed in other tumour types.
Interpretation: Nivolumab was safe and well tolerated in children and young adults and showed clinical activity in lymphoma. Nivolumab showed no significant single-agent activity in the common paediatric solid tumours. This study defines the recommended phase 2 dose and establishes a favourable safety profile for nivolumab in children and young adults, which can serve as the basis for its potential study in combinatorial regimens for childhood cancer.
Funding: Bristol-Myers Squibb, Children's Oncology Group, National Institutes of Health, Cookies for Kids Cancer Foundation.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All other authors declare no competing interests.
Figures
Comment in
-
Nivolumab in paediatric cancer: children are not little adults.Lancet Oncol. 2020 Apr;21(4):474-476. doi: 10.1016/S1470-2045(20)30086-3. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192574 No abstract available.
Similar articles
-
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
-
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0. Lancet Haematol. 2020. PMID: 32853585 Free PMC article. Clinical Trial.
-
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.Lancet Oncol. 2021 Dec;22(12):1764-1776. doi: 10.1016/S1470-2045(21)00536-2. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780709 Clinical Trial.
-
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.Curr Hematol Malig Rep. 2018 Dec;13(6):543-554. doi: 10.1007/s11899-018-0484-4. Curr Hematol Malig Rep. 2018. PMID: 30338457 Review.
-
AYA Considerations for Aggressive Lymphomas.Curr Hematol Malig Rep. 2021 Feb;16(1):61-71. doi: 10.1007/s11899-021-00607-7. Epub 2021 Mar 16. Curr Hematol Malig Rep. 2021. PMID: 33728589 Review.
Cited by
-
What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?Curr Treat Options Oncol. 2024 Jun;25(6):784-797. doi: 10.1007/s11864-024-01206-3. Epub 2024 May 16. Curr Treat Options Oncol. 2024. PMID: 38750399 Review.
-
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy.Cancers (Basel). 2024 Apr 25;16(9):1648. doi: 10.3390/cancers16091648. Cancers (Basel). 2024. PMID: 38730598 Free PMC article. Review.
-
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.Cancer Med. 2024 Apr;13(8):e7154. doi: 10.1002/cam4.7154. Cancer Med. 2024. PMID: 38629258 Free PMC article.
-
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.Front Cell Dev Biol. 2024 Mar 27;12:1353860. doi: 10.3389/fcell.2024.1353860. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38601081 Free PMC article. Review.
-
Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy.Int J Mol Sci. 2024 Mar 12;25(6):3225. doi: 10.3390/ijms25063225. Int J Mol Sci. 2024. PMID: 38542199 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials